{
    "references": [
        {
            "bibentry": "Sibbing, D, Aradi, D, Alexopoulos, D. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y, 12 receptor inhibitor treatment in percutaneous coronary intervention, JACC Cardiovasc Interv, 2019, 12, 1521, 1537, PMID: 31202949",
            "process_entry": "True",
            "doi": "10.1016/j.jcin.2019.03.034",
            "pmid": "31202949",
            "xmlid": "B1"
        },
        {
            "bibentry": "Jaitner, J, Stegherr, J, Morath, T. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients, Thromb Haemost, 2011, 105, 107, 112, PMID: 20978709",
            "process_entry": "True",
            "doi": "10.1160/th10-07-0440",
            "pmid": "20978709",
            "xmlid": "B2"
        },
        {
            "bibentry": "Campo, G, Parrinello, G, Ferraresi, P. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome, J Am Coll Cardiol, 2011, 57, 2474, 2483, PMID: 21679849",
            "process_entry": "True",
            "doi": "10.1016/j.jacc.2010.12.047",
            "pmid": "21679849",
            "xmlid": "B3"
        },
        {
            "bibentry": "Hochholzer, W, Ruff, CT, Mesa, RA. Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial, J Am Coll Cardiol, 2014, 64, 361, 368, PMID: 25060370",
            "process_entry": "True",
            "doi": "10.1016/j.jacc.2014.03.051",
            "pmid": "25060370",
            "xmlid": "B4"
        },
        {
            "bibentry": "Yun, KH, Cho, JY, Rhee, SJ, Oh, SK. Temporal variability of platelet reactivity in patients treated with clopidogrel or ticagrelor, Korean Circ J, 2019, 49, 1052, 1061",
            "process_entry": "True",
            "xmlid": "B5"
        },
        {
            "bibentry": "Gurbel, PA, Bliden, KP, Butler, K. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study, Circulation, 2009, 120, 2577, 2585, PMID: 19923168",
            "process_entry": "True",
            "doi": "10.1161/circulationaha.109.912550",
            "pmid": "19923168",
            "xmlid": "B6"
        },
        {
            "bibentry": "Wallentin, L, Becker, RC, Budaj, A. Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 2009, 361, 1045, 1057, PMID: 19717846",
            "process_entry": "True",
            "doi": "10.1056/nejmoa0904327",
            "pmid": "19717846",
            "xmlid": "B7"
        },
        {
            "bibentry": "Wiviott, SD, Braunwald, E, McCabe, CH. Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 2007, 357, 2001, 2015, PMID: 17982182",
            "process_entry": "True",
            "doi": "10.1056/nejmoa0706482",
            "pmid": "17982182",
            "xmlid": "B8"
        },
        {
            "bibentry": "Alexopoulos, D, Xanthopoulou, I, Mavronasiou, E. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes, Diabetes Care, 2013, 36, 2211, 2216, PMID: 23491524",
            "process_entry": "True",
            "doi": "10.2337/dc12-2510",
            "pmid": "23491524",
            "pmcid": "PMC3714492",
            "xmlid": "B9"
        },
        {
            "bibentry": "Huo, Y, Jeong, YH, Gong, Y. 2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI, Sci Bull (Beijing), 2019, 64, 166, 179",
            "process_entry": "True",
            "xmlid": "B10"
        }
    ],
    "localid": "MED-31646771",
    "doi": "10.4070/kcj.2019.0260",
    "pmid": "10.4070/kcj.2019.0260",
    "pmcid": "31646771",
    "curator": "BEE EuropeanPubMedCentralProcessor",
    "source_provider": "Europe PubMed Central",
    "source": "https://www.ebi.ac.uk/europepmc/webservices/rest/31646771/fullTextXML",
    "reference_pointers": [
        [
            {
                "n_rp": 0,
                "xref_id": "B1",
                "rp_string": "1)",
                "rp_xpath": "/article/body/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/p[1]),1,418)",
                "containers_title": ""
            }
        ],
        [
            {
                "n_rp": 1,
                "xref_id": "B1",
                "rp_string": "1)",
                "rp_xpath": "/article/body/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/p[1]),595,453)",
                "containers_title": ""
            }
        ],
        [
            {
                "n_rp": 2,
                "xref_id": "B1",
                "rp_string": "1)",
                "rp_xpath": "/article/body/p[2]/xref[1]",
                "context_xpath": "substring(string(/article/body/p[2]),1,369)",
                "containers_title": ""
            }
        ],
        [
            {
                "n_rp": 3,
                "xref_id": "B1",
                "rp_string": "1)",
                "rp_xpath": "/article/body/p[2]/xref[2]",
                "context_xpath": "substring(string(/article/body/p[2]),1128,292)",
                "containers_title": ""
            }
        ],
        [
            {
                "n_rp": 4,
                "xref_id": "B2",
                "rp_string": "2)",
                "rp_xpath": "/article/body/p[2]/xref[3]",
                "context_xpath": "substring(string(/article/body/p[2]),1128,292)",
                "containers_title": ""
            }
        ],
        [
            {
                "n_rp": 5,
                "xref_id": "B5",
                "rp_string": "5)",
                "rp_xpath": "/article/body/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/p[3]),1,241)",
                "containers_title": ""
            }
        ],
        [
            {
                "n_rp": 6,
                "xref_id": "B1",
                "rp_string": "1)",
                "rp_xpath": "/article/body/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/p[3]),243,477)",
                "containers_title": ""
            }
        ],
        [
            {
                "n_rp": 7,
                "xref_id": "B6",
                "rp_string": "6)",
                "rp_xpath": "/article/body/p[4]/xref[1]",
                "context_xpath": "substring(string(/article/body/p[4]),483,437)",
                "containers_title": ""
            }
        ],
        [
            {
                "n_rp": 8,
                "xref_id": "B2",
                "rp_string": "2)",
                "rp_xpath": "/article/body/p[4]/xref[2]",
                "context_xpath": "substring(string(/article/body/p[4]),1372,180)",
                "containers_title": ""
            }
        ],
        [
            {
                "n_rp": 9,
                "xref_id": "B3",
                "rp_string": "3)",
                "rp_xpath": "/article/body/p[4]/xref[3]",
                "context_xpath": "substring(string(/article/body/p[4]),1372,180)",
                "containers_title": ""
            }
        ],
        [
            {
                "n_rp": 10,
                "xref_id": "B4",
                "rp_string": "4)",
                "rp_xpath": "/article/body/p[4]/xref[4]",
                "context_xpath": "substring(string(/article/body/p[4]),1372,180)",
                "containers_title": ""
            }
        ],
        [
            {
                "n_rp": 11,
                "xref_id": "B7",
                "rp_string": "7)",
                "rp_xpath": "/article/body/p[5]/xref[1]",
                "context_xpath": "substring(string(/article/body/p[5]),1,443)",
                "containers_title": ""
            }
        ],
        [
            {
                "n_rp": 12,
                "xref_id": "B5",
                "rp_string": "5)",
                "rp_xpath": "/article/body/p[5]/xref[4]",
                "context_xpath": "substring(string(/article/body/p[5]),445,655)",
                "containers_title": "",
                "pl_string": "Potent P2Y12 inhibitors inevitably increased the risk of major bleeding in ACS patients, compared with clopidogrel.7)8) Meanwhile, the antiplatelet effect on ticagrelor vs. prasugrel treatment appears greater in ACS patients.9) Platelet reactivity at 30-day post-PCI in patients on ticagrelor was lower than those on prasugrel following acute myocardial infarction (21.1±26.1 vs. 67.3±62.5 P2Y12 reaction units measured by VerifyNow; p<0.001). In the present study, ticagrelor treatment almost abolished the risk of HPR, but more than 50% of the patients had LPR phenotype (≤18 U).5) Absolute increase of non-CABG TIMI major bleeding (+0.6%) seemed similar between ticagrelor and prasugrel, compared with clopidogrel.7)8) Compared with the short plasma exposure of thienopyridine (prasugrel and clopidogrel) active metabolites (up to 6 hours), ticagrelor has significant 24-hour systemic exposure of a direct active compound (reversible-binding property)6); this unique profile of ticagrelor may be characterized by its fast and strong platelet inhibition with a wider therapeutic window (Figure 1). The dedicated clinical studies to indicate the different cutoffs of LPR during thienopyridine or ticagrelor treatment are needed to guide the tailored strategy to target the therapeutic window of platelet reactivity.",
                "pl_xpath": "/article/body/p[5]"
            },
            {
                "n_rp": 13,
                "xref_id": "B7",
                "rp_string": "7)",
                "rp_xpath": "/article/body/p[5]/xref[5]",
                "context_xpath": "substring(string(/article/body/p[5]),445,655)",
                "containers_title": "",
                "pl_string": "Potent P2Y12 inhibitors inevitably increased the risk of major bleeding in ACS patients, compared with clopidogrel.7)8) Meanwhile, the antiplatelet effect on ticagrelor vs. prasugrel treatment appears greater in ACS patients.9) Platelet reactivity at 30-day post-PCI in patients on ticagrelor was lower than those on prasugrel following acute myocardial infarction (21.1±26.1 vs. 67.3±62.5 P2Y12 reaction units measured by VerifyNow; p<0.001). In the present study, ticagrelor treatment almost abolished the risk of HPR, but more than 50% of the patients had LPR phenotype (≤18 U).5) Absolute increase of non-CABG TIMI major bleeding (+0.6%) seemed similar between ticagrelor and prasugrel, compared with clopidogrel.7)8) Compared with the short plasma exposure of thienopyridine (prasugrel and clopidogrel) active metabolites (up to 6 hours), ticagrelor has significant 24-hour systemic exposure of a direct active compound (reversible-binding property)6); this unique profile of ticagrelor may be characterized by its fast and strong platelet inhibition with a wider therapeutic window (Figure 1). The dedicated clinical studies to indicate the different cutoffs of LPR during thienopyridine or ticagrelor treatment are needed to guide the tailored strategy to target the therapeutic window of platelet reactivity.",
                "pl_xpath": "/article/body/p[5]"
            },
            {
                "n_rp": 14,
                "xref_id": "B8",
                "rp_string": "8)",
                "rp_xpath": "/article/body/p[5]/xref[6]",
                "context_xpath": "substring(string(/article/body/p[5]),445,655)",
                "containers_title": "",
                "pl_string": "Potent P2Y12 inhibitors inevitably increased the risk of major bleeding in ACS patients, compared with clopidogrel.7)8) Meanwhile, the antiplatelet effect on ticagrelor vs. prasugrel treatment appears greater in ACS patients.9) Platelet reactivity at 30-day post-PCI in patients on ticagrelor was lower than those on prasugrel following acute myocardial infarction (21.1±26.1 vs. 67.3±62.5 P2Y12 reaction units measured by VerifyNow; p<0.001). In the present study, ticagrelor treatment almost abolished the risk of HPR, but more than 50% of the patients had LPR phenotype (≤18 U).5) Absolute increase of non-CABG TIMI major bleeding (+0.6%) seemed similar between ticagrelor and prasugrel, compared with clopidogrel.7)8) Compared with the short plasma exposure of thienopyridine (prasugrel and clopidogrel) active metabolites (up to 6 hours), ticagrelor has significant 24-hour systemic exposure of a direct active compound (reversible-binding property)6); this unique profile of ticagrelor may be characterized by its fast and strong platelet inhibition with a wider therapeutic window (Figure 1). The dedicated clinical studies to indicate the different cutoffs of LPR during thienopyridine or ticagrelor treatment are needed to guide the tailored strategy to target the therapeutic window of platelet reactivity.",
                "pl_xpath": "/article/body/p[5]"
            },
            {
                "n_rp": 15,
                "xref_id": "B6",
                "rp_string": "6)",
                "rp_xpath": "/article/body/p[5]/xref[7]",
                "context_xpath": "substring(string(/article/body/p[5]),445,655)",
                "containers_title": "",
                "pl_string": "Potent P2Y12 inhibitors inevitably increased the risk of major bleeding in ACS patients, compared with clopidogrel.7)8) Meanwhile, the antiplatelet effect on ticagrelor vs. prasugrel treatment appears greater in ACS patients.9) Platelet reactivity at 30-day post-PCI in patients on ticagrelor was lower than those on prasugrel following acute myocardial infarction (21.1±26.1 vs. 67.3±62.5 P2Y12 reaction units measured by VerifyNow; p<0.001). In the present study, ticagrelor treatment almost abolished the risk of HPR, but more than 50% of the patients had LPR phenotype (≤18 U).5) Absolute increase of non-CABG TIMI major bleeding (+0.6%) seemed similar between ticagrelor and prasugrel, compared with clopidogrel.7)8) Compared with the short plasma exposure of thienopyridine (prasugrel and clopidogrel) active metabolites (up to 6 hours), ticagrelor has significant 24-hour systemic exposure of a direct active compound (reversible-binding property)6); this unique profile of ticagrelor may be characterized by its fast and strong platelet inhibition with a wider therapeutic window (Figure 1). The dedicated clinical studies to indicate the different cutoffs of LPR during thienopyridine or ticagrelor treatment are needed to guide the tailored strategy to target the therapeutic window of platelet reactivity.",
                "pl_xpath": "/article/body/p[5]"
            }
        ],
        [
            {
                "n_rp": 16,
                "xref_id": "B1",
                "rp_string": "1)",
                "rp_xpath": "/article/body/p[6]/xref[1]",
                "context_xpath": "substring(string(/article/body/p[6]),1,791)",
                "containers_title": ""
            }
        ],
        [
            {
                "n_rp": 17,
                "xref_id": "B1",
                "rp_string": "1)",
                "rp_xpath": "/article/body/p[7]/xref",
                "context_xpath": "substring(string(/article/body/p[7]),1,517)",
                "containers_title": ""
            }
        ],
        [
            {
                "n_rp": 18,
                "xref_id": "B6",
                "rp_string": "6)",
                "rp_xpath": "/article/floats-group/fig/caption/title/xref",
                "context_xpath": "substring(string(/article/floats-group/fig/caption/title),1,116)",
                "containers_title": [
                    "Conceptual therapeutic window of platelet reactivity during irreversible and reversible P2Y12 receptor inhibitors.6)"
                ]
            }
        ],
        [
            {
                "n_rp": 19,
                "xref_id": "B1",
                "rp_string": "1)",
                "rp_xpath": "/article/floats-group/table-wrap/caption/title/xref",
                "context_xpath": "substring(string(/article/floats-group/table-wrap/caption/title),1,44)",
                "containers_title": [
                    "Consensus cutoffs to determine HPR and LPR1)"
                ]
            }
        ]
    ]
}